Phase II trial of didemnin-B in advanced epithelial ovarian cancer. A Southwest Oncology Group study.
A Phase II study of Didemnin-B, a marine cyclic depsipeptide, was undertaken in patients with progressive epithelial ovarian cancer. The starting dose was 2.6 mg/m2. Fifteen patients received the drug, of whom twelve were evaluable. There were no responses observed in the twelve patients. The two most frequent toxicities were nausea and vomiting and anemia. On the basis of this trial, Didemnin-B is not felt to have significant effect with epithelial ovarian cancer.
Cain
J M
JM
Puget Sound Oncology Consortium, Seattle, WA.
Liu
P Y
PY
Alberts
D E
DE
Gallion
H H
HH
Laufman
L
L
O'Sullivan
J
J
Weiss
G
G
Bickers
J N
JN
D000368:Aged; D047630:Depsipeptides; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D010456:Peptides, Cyclic / Q000008:administration & dosage* / Q000009:adverse effects
D047630:Depsipeptides; D010456:Peptides, Cyclic; C030051:didemnins